TY - JOUR
T1 - Northern Territory Perspectives on Heart Failure With Comorbidities - Understanding Trial Validity and Exploring Collaborative Opportunities to Broaden the Evidence Base
AU - Iyngkaran, Pupalan
AU - Majoni, William
AU - Cass, Alan
AU - Sanders, Prash
AU - Ronco, Claudio
AU - Brady, Stephen
AU - Kangaharan, Nadarajah
AU - Ilton, Marcus
AU - Hare, D
AU - Thomas, M
PY - 2015/6/1
Y1 - 2015/6/1
N2 - Congestive Heart Failure (CHF) is an ambulatory care sensitive condition, associated with significant morbidity and mortality, rarely with cure. Outpatient based pharmacological management represents the main and most important aspect of care, and is usually lifelong. This narrative styled opinion review looks at the pharmacological agents recommended in the guidelines in context of the Northern Territory (NT) of Australia. We explore the concept of validity, a term used to describe the basis of standardising a particular trial or study and the population to which it is applicable. We aim to highlight the problems of the current guidelines based approach. We also present alternatives that could utilise the core principles from major trials, while incorporating regional considerations, which could benefit clients living in the NT and remote Australia.
AB - Congestive Heart Failure (CHF) is an ambulatory care sensitive condition, associated with significant morbidity and mortality, rarely with cure. Outpatient based pharmacological management represents the main and most important aspect of care, and is usually lifelong. This narrative styled opinion review looks at the pharmacological agents recommended in the guidelines in context of the Northern Territory (NT) of Australia. We explore the concept of validity, a term used to describe the basis of standardising a particular trial or study and the population to which it is applicable. We aim to highlight the problems of the current guidelines based approach. We also present alternatives that could utilise the core principles from major trials, while incorporating regional considerations, which could benefit clients living in the NT and remote Australia.
KW - Guidelines
KW - Heart Failure
KW - Indigenous Australians
KW - Remote
KW - Rural
KW - Therapeutics
UR - http://www.ncbi.nlm.nih.gov/pubmed/25637942
UR - http://www.scopus.com/inward/record.url?scp=84929952114&partnerID=8YFLogxK
U2 - 10.1016/j.hlc.2014.12.007
DO - 10.1016/j.hlc.2014.12.007
M3 - Review article
SN - 1443-9506
VL - 24
SP - 536
EP - 543
JO - Heart, Lung and Circulation
JF - Heart, Lung and Circulation
IS - 6
ER -